Molecular Response (PDX business unit) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

Molecular Response (PDX business unit) General Information

Description

Provider of translational oncology drug discovery services. The unit provides PDX models as well as 8000 viable human tumors for model development services.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Acquirer
Corporate Office
  • San Diego, CA 92121
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Molecular Response (PDX business unit) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Molecular Response (PDX business unit)‘s full profile, request access.

Request a free trial

Molecular Response (PDX business unit) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Molecular Response (PDX business unit)‘s full profile, request access.

Request a free trial

Molecular Response (PDX business unit) FAQs

  • Where is Molecular Response (PDX business unit) headquartered?

    Molecular Response (PDX business unit) is headquartered in San Diego, CA.

  • What industry is Molecular Response (PDX business unit) in?

    Molecular Response (PDX business unit)’s primary industry is Drug Discovery.

  • Is Molecular Response (PDX business unit) a private or public company?

    Molecular Response (PDX business unit) is a Private company.

  • What is Molecular Response (PDX business unit)’s current revenue?

    The current revenue for Molecular Response (PDX business unit) is 000000.

  • Who are Molecular Response (PDX business unit)’s investors?

    Molecular Response has invested in Molecular Response (PDX business unit).

  • When was Molecular Response (PDX business unit) acquired?

    Molecular Response (PDX business unit) was acquired on 12-Feb-2015.

  • Who acquired Molecular Response (PDX business unit)?

    Molecular Response (PDX business unit) was acquired by Crown Bioscience.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »